Orchid Cellmark has named James Smith to the post of VP and CFO. Smith formerly was executive VP and CFO of Aphton, and before that he was VP and global controller of Ansell/Smith. He also served as a senior executive in finance and accounting at Wyeth and American Cyanamid Company.
John Quackenbush has joined Dermtech’s scientific advisory board. Quackenbush is a professor of biostatistics and computational biology at the Dana-Farber Cancer Institute and a professor of computational biology and bioinformatics at the Harvard School of Public Health.
Transgenomic has named Chad Richards as senior VP of sales and marketing. Richards formerly was national sales director of the Cancer Diagnostics Division for Quest Diagnostics, and before that he was involved in sales and marketing at Ventana Medical Systems.
Oxford Genome Sciences has added Walter Bodmer to its scientific advisory board. Bodmer is head of the Cancer and Immunogenetics laboratory in the Weatherall Institute of Molecular Medicine at the University of Oxford. Bodmer formerly was director general of the Imperial Cancer Research Fund for a dozen years, and before that he was a professor of genetics at Oxford.
Third Wave Technologies has appointed David Arnold to its board of directors. Arnold is a former VP and CTO of Kennametal, where he worked for 24 years.
Epigenomics has named the first members for its new colorectal cancer medical advisory board. Appointees include Douglas Rex, professor of medicine at Indiana University’s School of Medicine; Philip Schoenfeld, associate professor in the department of internal medicine at the University of Michigan’s School of Medicine; Deborah Fisher, assistant professor of medicine at Duke University; and Scott Ramsey, associate professor of medicine and health services at the Fred Hutchinson Cancer Research Center.